EGTX — Egetis Therapeutics AB (publ) Balance Sheet
0.000.00%
Last trade - 00:00
- SEK1.34bn
- SEK1.26bn
- SEK57.60m
R2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Interim Report | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 255 | 288 | 144 | 128 | 303 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 6.9 | 6.84 | 6.8 | 10.2 | 36.4 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 270 | 300 | 153 | 147 | 346 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | — | 4.74 | 4.28 | 2.7 | 4.4 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 270 | 717 | 569 | 561 | 760 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 25.1 | 70.1 | 39.2 | 49.4 | 104 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 25.1 | 86.3 | 42.2 | 54.9 | 215 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 245 | 631 | 527 | 506 | 546 |
Total Liabilities & Shareholders' Equity | 270 | 717 | 569 | 561 | 760 |
Total Common Shares Outstanding |